News

03.01.23 Medannex features in global pharmaceutical publication ‘Scrip’
12.12.22 Regulators give green light to first-in-human study with MDX-124
08.04.22 Medannex’s first-in-class agent shows significant activity against clinically challenging cancers
21.01.22 Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models
10.12.21 Medannex’s new therapy shows powerful synergy with common cancer treatments
10.09.21 Medannex team leads the field in BIA charity fundraiser
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5